文献速递肿瘤 PET/CT

PSMA与非PSMA PET示踪剂在复发性和原发性前列腺癌中的检测性能比较:系统综述与网络荟萃分析

Comparative Detection Performance of PSMA and Non-PSMA PET Tracers in Recurrent and Primary Prostate Cancer: A Systematic Review and Network Meta-Analysis.
PubMed 文献 · Clin Nucl Med · 2026-03-25

该系统综述与网络荟萃分析纳入比较两种PET示踪剂用于前列腺癌的研究,主要结局为检出率。结果显示,在生化复发前列腺癌中,PSMA靶向示踪剂检出率高于非PSMA示踪剂;在PSMA示踪剂中,18F标记的18F-PSMA-1007和18F-DCFPyL在原发性和复发性前列腺癌中检出率均高于68Ga-PSMA-11。

要点

  • 生化复发前列腺癌中PSMA示踪剂检出率高于非PSMA示踪剂。
  • 18F-PSMA-1007和18F-DCFPyL在原发和复发癌中检出率高于68Ga-PSMA-11。
  • 有条件时应优先选择18F标记的PSMA示踪剂。

核心结论

  • PSMA示踪剂在生化复发前列腺癌检测中优于非PSMA替代示踪剂。
  • 在PSMA示踪剂中,18F标记药物在原发性和生化复发前列腺癌中检出率均持续超过68Ga-PSMA-11。
  • 有条件时优先选择18F标记的PSMA示踪剂。

研究设计与样本

  • 遵循PRISMA-NMA指南,系统检索PubMed、Embase、Cochrane Library和ClinicalTrials.gov截至2025年3月比较两种PET示踪剂用于前列腺癌的研究。
  • 采用频率学派随机效应网络荟萃分析,以68Ga-PSMA-11为参照计算相对风险(RR)及95%CI,用QUADAS-2评价质量。

主要发现

  • 在生化复发前列腺癌中,PSMA靶向示踪剂检出率高于非PSMA示踪剂。
  • PSMA示踪剂中,64Cu-PSMA-617估计检出率最高,其后依次为18F-DCFPyL、18F-PSMA-1007和68Ga-PSMA-11。
  • 18F-PSMA-1007和18F-DCFPyL在原发性和复发性前列腺癌中检出率均高于68Ga-PSMA-11。

关键数值与推荐

  • 主要结局检出率定义为PET阳性患者或病灶的比例。
  • 多数领域偏倚风险低,但参考标准和时机方面仍存在不确定性。

临床怎么用

  • 生化复发前列腺癌分期或再分期时,优先选用PSMA靶向PET示踪剂而非非PSMA示踪剂。
  • 在PSMA示踪剂可及的情况下,优先选择18F-PSMA-1007或18F-DCFPyL而非68Ga-PSMA-11。

局限性

  • 直接比较不同示踪剂性能的数据仍然稀少,最优选择此前不确定。
  • 部分研究的参考标准和成像时机存在不确定性,可能影响偏倚风险评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) tracers have reshaped prostate cancer (PC) imaging, supplementing non-PSMA options such as choline-based agents. However, direct comparative performance data across tracers remain scarce, leaving the optimal choice uncertain. We therefore conducted a systematic review and network meta-analysis (NMA) to assess detection rates (DRs) among PET tracers used for primary and biochemically recurrent PC. METHODS: Following PRISMA-NMA guidelines, we systematically searched PubMed, Embase, Cochrane Library, and ClinicalTrials.gov through March 2025 for studies comparing 2 PET tracers for prostate cancer. The primary outcome was DR, defined as the proportion of PET-positive patients or lesions. Two reviewers independently extracted data on study design, patient demographics, and imaging parameters, and evaluated quality with QUADAS-2. We performed frequentist random-effects NMA to calculate relative risks (RRs) with 95% CIs, using 68 Ga-PSMA-11 as reference. RESULTS: Nineteen studies (1681 patients) addressed biochemical recurrence, and 6 (271 patients) targeted primary PC, with 2 overlapping. Risk of bias was low for most domains, though some uncertainty remained for reference standards and timing. In biochemically recurrent PC, PSMA-directed tracers achieved higher DRs than non-PSMA probes. Within the PSMA tracers, 64 Cu-PSMA-617 achieved the highest estimated DR, followed by 18 F-DCFPyL, 18 F-PSMA-1007, and 68 Ga-PSMA-11. Both 18 F-PSMA-1007 and 18 F-DCFPyL showed higher DRs than 68 Ga-PSMA-11 in primary and recurrent PC. CONCLUSIONS: PSMA tracers outperform non-PSMA alternatives for detecting biochemical recurrence. Among PSMA tracers, 18 F-labeled agents consistently surpass 68 Ga-PSMA-11 in both biochemically recurrent and primary PC. When available, 18 F-labeled PSMA tracers should be preferred.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Huang YE, Huang CK, Huang YT, et al. Comparative Detection Performance of PSMA and Non-PSMA PET Tracers in Recurrent and Primary Prostate Cancer: A Systematic Review and Network Meta-Analysis. Clin Nucl Med. 2026. PMID: 41945370. doi:10.1097/RLU.0000000000006349

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。